TY - JOUR
T1 - The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma
AU - Akiyama, Kosuke
AU - Ohga, Noritaka
AU - Maishi, Nako
AU - Hida, Yasuhiro
AU - Kitayama, Kazuko
AU - Kawamoto, Taisuke
AU - Osawa, Takahiro
AU - Suzuki, Yuko
AU - Shinohara, Nobuo
AU - Nonomura, Katsuya
AU - Shindoh, Masanobu
AU - Hida, Kyoko
PY - 2013/1
Y1 - 2013/1
N2 - Tumor angiogenesis is necessary for tumor progression and metastasis; therefore, tumor blood vessels are potential therapeutic targets in anticancer therapy. We previously reported that tumor endothelial cells (TECs) exhibit different phenotypes compared with normal endothelial cells (NECs), and microarray analyses of mouse TECs and NECs have shown that several genes are upregulated in TECs compared with NECs. Among these genes, the expression levels of prostaglandin F receptor (PTGFR) mRNA, which encodes the prostaglandin F receptor (FP), were higher in TECs than in NECs. It has been reported that FP and its ligand, prostaglandin F2α, are involved in tumor angiogenesis. However, there have been no reports of the expression of PTGFR in the tumor vessels of renal cell carcinoma (RCC). Thus, we isolated human TECs (hTECs) from RCCs. The expression levels of PTGFR mRNA were also upregulated in hTECs. In addition, immunostaining showed that the PTGFR was expressed in human tumor blood vessels in vivo. These findings suggested that PTGFR is a novel TEC marker and that it may be a novel target for antiangiogenic therapy for RCC.
AB - Tumor angiogenesis is necessary for tumor progression and metastasis; therefore, tumor blood vessels are potential therapeutic targets in anticancer therapy. We previously reported that tumor endothelial cells (TECs) exhibit different phenotypes compared with normal endothelial cells (NECs), and microarray analyses of mouse TECs and NECs have shown that several genes are upregulated in TECs compared with NECs. Among these genes, the expression levels of prostaglandin F receptor (PTGFR) mRNA, which encodes the prostaglandin F receptor (FP), were higher in TECs than in NECs. It has been reported that FP and its ligand, prostaglandin F2α, are involved in tumor angiogenesis. However, there have been no reports of the expression of PTGFR in the tumor vessels of renal cell carcinoma (RCC). Thus, we isolated human TECs (hTECs) from RCCs. The expression levels of PTGFR mRNA were also upregulated in hTECs. In addition, immunostaining showed that the PTGFR was expressed in human tumor blood vessels in vivo. These findings suggested that PTGFR is a novel TEC marker and that it may be a novel target for antiangiogenic therapy for RCC.
UR - http://www.scopus.com/inward/record.url?scp=84873870857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873870857&partnerID=8YFLogxK
U2 - 10.1111/pin.12031
DO - 10.1111/pin.12031
M3 - Article
C2 - 23356224
AN - SCOPUS:84873870857
SN - 1320-5463
VL - 63
SP - 37
EP - 44
JO - Pathology International
JF - Pathology International
IS - 1
ER -